Pharmacotherapies for substance use disorders – CCTD (90)
This study section reviews behavioral and mechanistic studies focused on the use of pharmacotherapies to reduce and treat substance misuse including alcohol use disorders (AUD), smoking cessation, nicotine dependence, cocaine use disorder, methamphetamine use disorders, stimulant use disorders, psychostimulants, cannabis, and other opioid use disorders. Applications can include clinical trials, intervention studies, small clinical studies, mechanistic studies. This panel does not review applications at the molecular or cellular level or PK/PD studies. The study section does not review applications investigating genetic influences or gene identification studies. Applications reviewed in PSUD should have a social, behavioral, psychosocial, cognitive, or biopsychosocial focus; those focusing on biological mechanisms are reviewed in other study sections. PSUD reviews studies in humans only.
Review Dates
A roster for the panel will be posted here, at least 30 days prior to the review meeting
Topics
- Preliminary assessments of how candidate pharmacotherapies for substance use disorders affect neurocognitive processes and mechanisms associated with addictive behaviors
- Pharmacotherapeutic treatments for substance misuse and behavioral pharmacology experiments to better design efficacious treatments
- Pharmacotherapeutic treatments and mobile medication adherence
- Novel pharmacotherapies to treat co-addiction
- Studies examining pharmacotherapeutic treatment adherence, including the effect of adherence on substance misuse outcomes, and methods for measuring adherence
- Studies examining pharmacotherapies used for tapering in human subjects with substance use disorders
- Studies examining the therapeutic effect of combined pharmacological treatments
- Sociodemographic and clinical outcome differences among individuals involved in pharmacotherapy treatment for substance use disorders
